Citations

Showing 10 of 108083 citations.

Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings
Hampel, Paul J. , Chaffee, Kari G. , King, Rebecca L. , Simonetto, Douglas A. , Achenbach, Sara J., Call, Timothy G. , Ding, Wei , Leis, José F., Chanan‐Khan, Asher , Bowen, Deborah A., Conte, Michael, Schwager, Susan M., Hanson, Curtis A. , Parikh, Sameer A. , Rabe, Kari G. , SIMONETTO, DOUGLAS, Achenbach, Sara, Ding, Wei , Kenderian, Saad S. , Chanan-Khan, Asher A., Conte, Michael J, Parikh, Sameer A , Hampel, Paul J , Larson, Melissa C. , Slager, Susan L. , Kay, Neil E. , Shanafelt, Tait D. , Simonetto, Douglas A

Mayo Clinic

American Journal of Hematology | September 22, 2017 | Volume: 92 | Issue: 12 | Pages: 1362-1369

10.1002/ajh.24915 | PMID 28940587 Get It

AbstractThe prevalence of liver dysfunction and its association with outcomes in patients with previously untreated chronic lymphocytic leukemia (CLL) is unknown. Newly diagnosed (<12 months) previously untreated CLL patients seen at Mayo Clinic, Rochester, MN between 9/1993 and 4/2016 who had baseline assessment of at least one liver function test (LFT) were included in this analysis. The prevalence of liver dysfunction at baseline, proportion of patients who acquired LFT abnormalities, time to first therapy (TTFT) and overall survival (OS) were assessed. An abnormal LFT was present in 82/2336 (3.5%) patients at diagnosis and was associated with advanced Rai stage (Rai III–IV) (21% vs. 6%; P < .001), lower hemoglobin (13.1 g/dL vs. 13.9 g/dL; P < .001), and lower platelet count (187 × 109/L vs. 200 × 109/L; P = .03). Additionally, 236 patients with normal LFTs at diagnosis developed acquired liver dysfunction during follow‐up. Patients with abnormal LFTs at diagnosis had a shorter OS compared to those with normal LFTs (HR 1.80 95% CI 1.13‐2.87; P = .014, adjusted for age, sex, Rai stage, and treatment), although TTFT was not different. Of 52 patients who underwent a liver biopsy, CLL was present in liver tissue in 39/52 (73%) patients, with the portal tracts the most common region involved. Histopathology findings of liver involvement by CLL had limited correlation with choice of CLL therapy. In conclusion, approximately 1 of 25 newly diagnosed CLL patients has abnormal LFTs at diagnosis. Although the TTFT was not different among patients with abnormal LFTs, these patients have a shorter OS compared to those with normal LFTs.
Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome
Harris, Lucinda A. , Baffy, Noemi

Mayo Clinic

Postgraduate Medicine | September 22, 2017 | Volume: 129 | Issue: 8 | Pages: 872-888

10.1080/00325481.2017.1383819 | PMID 28936910 Get It

Sex Differences in the Utilization and Outcomes of Surgical Aortic Valve Replacement for Severe Aortic Stenosis
Chaker, Zakeih, Badhwar, Vinay , Aljohani, Sami, Zack, Chad, Holmes, David R. , Rihal, Charanjit S. , Alqahtani, Fahad , Rihal, Charanjit S. , Alkhouli, Mohamad

Mayo Clinic

Journal of the American Heart Association | September 21, 2017 | Volume: 6 | Issue: 9 | Pages: No page available

10.1161/jaha.117.006370 | PMID 28935681 Get It

Background Studies assessing the differential impact of sex on outcomes of aortic valve replacement ( AVR ) yielded conflicting results. We sought to investigate sex‐related differences in AVR utilization, patient risk profile, and in‐hospital outcomes using the Nationwide Inpatient Sample. Methods and Results In total, 166 809 patients (63% male and 37% female) who underwent AVR between 2003 and 2014 were identified, and 48.5% had a concomitant cardiac surgery procedure. Compared with men, women were older and had more nonatherosclerotic comorbid conditions including hypertension, diabetes mellitus, obstructive pulmonary disease, atrial fibrillation/flutter, and anemia but fewer incidences of coronary and peripheral arterial disease and prior sternotomies. In‐hospital mortality was significantly higher in women (5.6% versus 4%, P <0.001). Propensity matching was performed to assess the impact of sex on the outcomes of isolated AVR and yielded 28 237 matched pairs of male and female participants. In the propensity‐matched groups, in‐hospital mortality was higher in women (3.3% versus 2.9%, P <0.001). Along with vascular complications and blood transfusion (6% versus 5.6%, P =0.027 and 40.4% versus 33.9%, P <0.001, respectively). Rates of stroke, permanent pacemaker implantation, and acute kidney injury requiring dialysis were similar (2.4% versus 2.4%, P =0.99; 6% versus 6.3%, P =0.15; and 1.4% versus 1.3%, P =0.14, respectively). Length of stay median and interquartile range were both similar between groups (7±6 days). Rates of nonhome discharge were higher among women (27.9% versus 19.6%, P <0.001). Conclusions Women have worse in‐hospital mortality following AVR compared with men. Coupled with the accumulating evidence suggesting higher magnitude of benefit of transcatheter AVR over AVR in women, women should perhaps be offered transcatheter AVR over AVR at a lower threshold than men.
Endobronchial Optical Coherence Tomography for Low-Risk Microscopic Assessment and Diagnosis of Idiopathic Pulmonary Fibrosis In Vivo
Adams, David C. , Wain, John C. , Muniappan, Ashok , Colby, Thomas V. , Mark, Eugene J., Kradin, Richard L. , Goulart, Hannah , Tager, Andrew M. , Suter, Melissa J., Hariri, Lida P. , Lanuti, Michael D. , Sharma, Amita , Mino-Kenudson, Mari A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | September 21, 2017 | Volume: 197 | Issue: 7 | Pages: 949-952

10.1164/rccm.201707-1446le | PMID 28934552 Get It

Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension
Mehanna, Mai , McDonough, Caitrin W. , Beitelshees, Amber L. , Gums, John G. , Chapman, Arlene B. , Schwartz, Gary L. , Johnson, Julie A. , Beitelshees, Amber L. , Turner, Stephen T. , Gong, Yan , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

The Journal of Clinical Hypertension | September 21, 2017 | Volume: 19 | Issue: 12 | Pages: 1301-1308

10.1111/jch.13094 | PMID 28940643 Get It

Despite the availability of many antihypertensive drug classes, half of patients with hypertension have uncontrolled blood pressure (BP). The authors sought to assess the effect of age on BP response in European American and African American patients with hypertension. Clinic BP from the PEAR2 (Pharmacogenomics Evaluation of Antihypertensive Responses 2) study was used to estimate BP responses from baseline following sequential treatment with metoprolol 100 mg twice daily and chlorthalidone 25 mg daily for 8 to 9 weeks each, with a minimum 4‐week washout between treatments. BP responses to both drugs were compared in 159 European Americans and 119 African Americans by age with adjustment for baseline BP and sex. European Americans younger than 50 years responded better to metoprolol than chlorthalidone (diastolic BP: −9.6 ± 8.0 vs −5.9 ± 6.8 mm Hg, adjusted P = .003), whereas patients 50 years and older responded better to chlorthalidone than metoprolol (systolic BP: −18.7 ± 13.8 vs −13.6 ± 14.8 mm Hg, adjusted P = .008). African Americans younger than 50 years responded similarly to both drugs, whereas those 50 years and older responded better to chlorthalidone than metoprolol (−17.0 ± 13.2/−9.6 ± 7.5 vs −7.0 ± 18.6/−6.7 ± 9.3 mm Hg, adjusted P<.0001/.008). Therefore, age should be considered when selecting antihypertensive therapy in European and African American populations with hypertension.
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial
Khorana, Alok A. , Vadhan‐Raj, Saroj , Kuderer, Nicole M. , Wun, Ted , Liebman, Howard A. , Soff, Gerald A. , O’Reilly, Eileen M. , McBane, Robert D. , Damaraju, C. V. , Beyers, Karen, Dietrich, Flavia, Kakkar, Ajay K. , Riess, Hanno, McBane, Robert , O'Reilly, Eileen M , Wun, Ted , Belani, Chandra P. , Eikelboom, John W. , Peixoto, Renata D’Alpino , Lyman, Gary H

Mayo Clinic

Thrombosis and Haemostasis | September 21, 2017 | Volume: 117 | Issue: 11 | Pages: 2135-2145

10.1160/th17-03-0171 | PMID 28933799 Get It

AbstractVenous thromboembolism (VTE) is a frequent complication of cancer associated with morbidity, mortality, increased hospitalizations and higher health care costs. Cancer patients at increased risk for VTE can be identified using a validated risk assessment score, and the incidence of VTE can be reduced in high-risk settings using anticoagulation. Rivaroxaban is a potent, oral, direct, factor Xa inhibitor approved for the prevention and treatment of thromboembolic events, including VTE. CASSINI is a double-blind, randomized, parallel-group, multicentre study comparing rivaroxaban with placebo in adult ambulatory patients with various cancers who are initiating systemic cancer therapy and are at high risk of VTE (Khorana score ≥ 2). Patients with primary brain tumours or those at risk for bleeding are excluded. Approximately 700 patients will be randomized 1:1 to rivaroxaban 10 mg daily or placebo for up to 6 months if there is no evidence of VTE from compression ultrasonography (CU) during screening or from routine care imaging within 30 days prior to randomization. Mandatory CU will also be performed at weeks 8 and 16 (±7 days), and at study end (±3 days). The primary efficacy hypothesis is that anticoagulation with rivaroxaban reduces the composite of objectively confirmed symptomatic or asymptomatic, lower-extremity, proximal deep-vein thrombosis (DVT); symptomatic, upper-extremity DVT; symptomatic or incidental pulmonary embolism; and VTE-related death compared with placebo. The primary safety objective is to assess major bleeding events (Clinical trial information: NCT02555878).
Sex differences in associations of cardio-ankle vascular index with left ventricular function and geometry
Ye, Zi , Pellikka, Patricia A. , Pellikka, Patricia A , Kullo, Iftikhar J.

Mayo Clinic

Vascular Medicine | September 21, 2017 | Volume: 22 | Issue: 6 | Pages: 465-472

10.1177/1358863x17725810 | PMID 28931350 Get It

The cardio-ankle vascular index (CAVI) is a measure of global arterial stiffness. We hypothesized that CAVI is associated with left ventricular (LV) function and geometry in individuals without structural heart disease. We measured CAVI in 600 participants (mean age 60.3±14.6 years, 54% men) without history of atherosclerotic cardiovascular disease who were referred for transthoracic echocardiography. Linear regression analysis was used to assess the association of CAVI with LV function (peak mitral annular systolic s’ and early diastolic velocity e’) and structure (LV mass index (LVMI) and relative wall thickness (RWT)). Older age, male sex, lower body mass index, history of hypertension, diabetes and chronic kidney disease were each associated with a higher CAVI (adjusted R 2 = 0.56, all p < 0.01). A higher CAVI was associated with lower s’ and e’, and greater RWT, independent of age, sex, systolic BP and other conventional cardiovascular risk factors (all p < 0.05); a borderline association of higher CAVI with greater LVMI ( p = 0.05) was present. Associations with e’, s’ and RWT were similar in women and men but the association with LVMI was stronger in women than in men ( p for interaction = 0.02, multivariable-adjusted β = 6.92, p < 0.001 in women; p > 0.1 in men). In conclusion, a higher CAVI, a measure of global arterial stiffness, is associated with worse LV systolic function, worse diastolic relaxation, and greater LV RWT in both men and women, and with LVMI in women.
Effects of intravenous low-dose dopamine infusion on glucose regulation during prolonged aerobic exercise
Johnson, Blair D. , Ranadive, Sushant M. , Curry, Timothy B. , Joyner, Michael J. , Ranadive, Sushant M. , Peinado, Ana B, Johnson, Blair D , Joyner, Michael J , Peinado, Ana B. , Ranadive, Sushant

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | September 21, 2017 | Volume: 314 | Issue: 1 | Pages: R49-R57

10.1152/ajpregu.00030.2017 | PMID 28931543 Get It

The carotid body chemoreceptors are activated during hypoglycemia and contribute to glucoregulation during prolonged exercise in dogs. Low-dose intravenous infusions of dopamine have been shown to blunt the activation of the carotid body chemoreceptors during hypoxia. Therefore, we tested the hypotheses that dopamine would blunt glucoregulatory responses and attenuate plasma glucose during prolonged aerobic exercise in healthy participants. Twelve healthy participants completed two randomized exercise sessions at 65% peak oxygen consumption for up to 120 min. Saline was infused during one exercise session, and dopamine (2 μg·kg−1·min−1) was infused during the other session. Arterial plasma glucose, growth hormone, glucagon, cortisol, norepinephrine, and epinephrine were measured every 10 min. Exercise duration during dopamine infusion was 107 ± 6 and 119 ± 0.8 min during saline infusion. Glucose area under the curve during exercise was lower during dopamine (9,821 ± 686 vs. 11,194 ± 395 arbitrary units; P = 0.016). The ratio of circulating growth hormone to glucose and the ratio of glucagon to glucose were greater during dopamine ( P = 0.045 and 0.037, respectively). These results indicate that the infusion of dopamine during aerobic exercise impairs glucoregulation. This suggests that the carotid body chemoreceptors contribute to glucoregulation during prolonged exercise in healthy exercise-trained humans.
Genome editing technologies and their potential to treat neurologic disease
Madigan, Nicolas N. , Staff, Nathan P. , Windebank, Anthony J. , Benarroch, Eduardo E. , Staff, Nathan P

Mayo Clinic

Neurology | September 21, 2017 | Volume: 89 | Issue: 16 | Pages: 1739-1748

10.1212/wnl.0000000000004558 | PMID 28931646 Get It

Patient Burden of Axial Spondyloarthritis
Singh, Jasvinder A. , Strand, Vibeke, Singh, Jasvinder A , Strand, Vibeke

Mayo Clinic

JCR: Journal of Clinical Rheumatology | September 20, 2017 | Volume: 23 | Issue: 7 | Pages: 383-391

10.1097/rhu.0000000000000589 | PMID 28937474 Get It

Abstract Axial spondyloarthritis (AxSpA) is an inflammatory spondyloarthritis (SpA) that has significant impact on a patient's life. Symptoms, including fatigue, sleep problems, depression, and sexual dysfunction, can profoundly impact health-related quality of life (HRQoL) and limit work, leisure, and daily activities. Available therapies effectively manage pain and inflammation in early-stage disease, but patients often continue to experience impaired HRQoL. Thus, there remains a need for new therapies with novel mechanisms that can stop disease progression, potentially reverse damage caused by AxSpA and improve HRQoL in patients with AxSpA. Newer biologic agents, such as those targeting the interleukin 17–interleukin 23 axis, have promising efficacy and may improve HRQoL for patients with AxSpA. The AxSpA has many negative effects on HRQoL. By targeting disease pathways responsible for the development of AxSpA, approved and emerging therapies potentially reduce disease activity and improve the functional status of patients with AxSpA. This narrative review reflects on the findings of studies evaluating HRQoL of individuals with AxSpA and the role of newer therapies.